Fused bicyclic kinase inhibitors

Abstract

Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.

1 . A compound of Formula I: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein: 
         X is selected from H, C 1-3 aliphatic, or —OC 1-3 aliphatic, either of which is optionally substituted with halo or —CN; 
         W—V is C—N or N—C; 
         Y 1  and Y 2  are independently N or CH, provided that not more than one of Y 1  and Y 2  is N; Y 3  is NH or CH; Y 4  is N or CH; Y 5  is N or C, provided that not more than one of Y 4  and Y 5  is N; 
         R 1a , R 1b , R 1c , R 1d , R 1e  are each independently selected from H, aliphatic, cyclic, —O-aliphatic, —O-cyclic, sulfide, sulfone, sulfoxide, amino, amido, carboxyl, acyl, ureido, or S-cyclic, any of the foregoing being optionally substituted, halo, or —CN; 
         G1 is selected from H, aliphatic, or cyclic, either of which is optionally substituted; 
         R17 and R18 are independently selected from H, aliphatic, —O-aliphatic, cyclic, amido, carboxyl, or amino, any of the foregoing being optionally substituted, —CN, or halo, provided that at least one of R17 and R18 is not H. 
       
     
     
         2 - 30 . (canceled)